118 related articles for article (PubMed ID: 35924450)
1. Comparing the associations between host and tumor factors with survival outcomes with anti-PD-1 immunotherapy in metastatic melanoma.
Koczka K; Rigo R; Batuyong E; Cook S; Asad M; Vallerand I; Suo A; Wang E; Cheng T
Cancer Med; 2023 Feb; 12(3):2427-2439. PubMed ID: 35924450
[TBL] [Abstract][Full Text] [Related]
2. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab.
Lorentzen CL; Kjeldsen JW; Ehrnrooth E; Andersen MH; Marie Svane I
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37217243
[TBL] [Abstract][Full Text] [Related]
4. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
6. Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
Tumori; 2019 Dec; 105(6):465-473. PubMed ID: 31446882
[TBL] [Abstract][Full Text] [Related]
7. High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy.
Dercle L; Ammari S; Roblin E; Bigorgne A; Champiat S; Taihi L; Plaian A; Hans S; Lakiss S; Tselikas L; Rouanne M; Deutsch E; Schwartz LH; Gönen M; Flynn J; Massard C; Soria JC; Robert C; Marabelle A
Eur J Cancer; 2022 Dec; 177():80-93. PubMed ID: 36332438
[TBL] [Abstract][Full Text] [Related]
8. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
9. Lactate Dehydrogenase Prior to Transarterial Hepatic Chemoperfusion Predicts Survival and Time to Progression in Patients with Uveal Melanoma Liver Metastases.
Ludwig J; Haubold J; Heusner TA; Bauer S; Siveke JT; Richly H; Wetter A; Umutlu L; Theysohn JM
Rofo; 2021 Jun; 193(6):683-691. PubMed ID: 33348383
[TBL] [Abstract][Full Text] [Related]
10. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
Dimitriou F; Namikawa K; Reijers ILM; Buchbinder EI; Soon JA; Zaremba A; Teterycz P; Mooradian MJ; Armstrong E; Nakamura Y; Vitale MG; Tran LE; Bai X; Allayous C; Provent-Roy S; Indini A; Bhave P; Farid M; Kähler KC; Mehmi I; Atkinson V; Klein O; Stonesifer CJ; Zaman F; Haydon A; Carvajal RD; Hamid O; Dummer R; Hauschild A; Carlino MS; Mandala M; Robert C; Lebbe C; Guo J; Johnson DB; Ascierto PA; Shoushtari AN; Sullivan RJ; Cybulska-Stopa B; Rutkowski P; Zimmer L; Sandhu S; Blank CU; Lo SN; Menzies AM; Long GV
Ann Oncol; 2022 Sep; 33(9):968-980. PubMed ID: 35716907
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
12. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
Wagner NB; Forschner A; Leiter U; Garbe C; Eigentler TK
Br J Cancer; 2018 Aug; 119(3):339-346. PubMed ID: 29950611
[TBL] [Abstract][Full Text] [Related]
13. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
Diem S; Kasenda B; Spain L; Martin-Liberal J; Marconcini R; Gore M; Larkin J
Br J Cancer; 2016 Feb; 114(3):256-61. PubMed ID: 26794281
[TBL] [Abstract][Full Text] [Related]
14. Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
Betof AS; Nipp RD; Giobbie-Hurder A; Johnpulle RAN; Rubin K; Rubinstein SM; Flaherty KT; Lawrence DP; Johnson DB; Sullivan RJ
Oncologist; 2017 Aug; 22(8):963-971. PubMed ID: 28476944
[TBL] [Abstract][Full Text] [Related]
15. Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis.
Zhao J; Li D; Xie S; Deng X; Wen X; Li J; Wu Z; Yang X; Li M; Tang Y; Zhang X; Ding Y
Front Immunol; 2022; 13():1083840. PubMed ID: 36618343
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis.
Xu J; Zhao J; Wang J; Sun C; Zhu X
Medicine (Baltimore); 2021 Apr; 100(14):e25318. PubMed ID: 33832106
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence.
Cybulska-Stopa B; Rogala P; Czarnecka AM; Ługowska I; Teterycz P; Galus Ł; Rajczykowski M; Dawidowska A; Piejko K; Suwiński R; Mackiewicz J; Rutkowski P
Adv Med Sci; 2020 Sep; 65(2):316-323. PubMed ID: 32554313
[TBL] [Abstract][Full Text] [Related]
19. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort.
Fornarini G; Rebuzzi SE; Banna GL; Calabrò F; Scandurra G; De Giorgi U; Masini C; Baldessari C; Naglieri E; Caserta C; Manacorda S; Maruzzo M; Milella M; Buttigliero C; Tambaro R; Ermacora P; Morelli F; Nolè F; Astolfi C; Sternberg CN
ESMO Open; 2021 Jun; 6(3):100118. PubMed ID: 33984678
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Zhang Y; Liu B; Kotenko S; Li W
Medicine (Baltimore); 2022 Aug; 101(32):e29536. PubMed ID: 35960066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
